Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms
about
Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis.Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage.Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.Hepatocellular carcinoma: targeting of oncogenic signaling networks in TRAIL resistant cancer cells.Enhancing FTS (Salirasib) efficiency via combinatorial treatment.Inhibition of Hec1 as a novel approach for treatment of primary liver cancer.Synthesis and biological evaluation of hybrids from farnesylthiosalicylic acid and hydroxylcinnamic acid with dual inhibitory activities of Ras-related signaling and phosphorylated NF-κB.Synthesis and biological evaluation of novel farnesylthiosalicylic acid derivatives for cancer treatment.Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma.Ras Signaling Inhibitors Attenuate Disease in Adjuvant-Induced Arthritis via Targeting Pathogenic Antigen-Specific Th17-Type Cells.Silencing of survivin by YM155 induces apoptosis and growth arrest in hepatocellular carcinoma cells.YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.Multifunctionalized polyethyleneimine-based nanocarriers for gene and chemotherapeutic drug combination therapy through one-step assembly strategy.Enhancement of cisplatin cytotoxicity by Retigeric acid B involves blocking DNA repair and activating DR5 in prostate cancer cells.MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death.Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
P2860
Q34221779-7D1581C6-F467-4C26-B405-E22CD65D8A68Q35833213-2A6A1EFD-1C43-4908-80A5-A9858E2A6C2BQ35872060-6CE8DA57-7F7B-4AEB-BA8B-42B768A40C55Q36275798-8E8BBD71-DA91-41DA-A452-11F153C29C05Q36398758-FE31F4C4-039C-44CC-A794-43BEBF4669DDQ38231045-984D5CDD-10ED-4CEF-99F4-E77F52BB877DQ38367291-C2F46185-3FFE-44E6-B968-A667889B6C3AQ38974099-C2D2DAAF-9C1F-4CA8-983F-073584128510Q38992986-3ECD6332-0E48-440C-8AE0-4E5BB259D1DEQ39033581-E37CD15B-E4DD-480F-9203-F224602A27C7Q39118820-9E7219ED-6388-4620-8976-73DBA133C2ECQ40954990-6A24A9BC-B150-4DF5-8F66-316C646C7969Q42457038-E9C7FB27-74E4-4967-BC8C-62CA24A01606Q46889307-510AA034-0958-47C7-84CC-4F041DC820DEQ47169597-7B8E8183-4750-494A-85A9-9569B7E785C9Q49479651-D0F6F9F0-3511-4B74-A996-15FD8436C87BQ50881835-9170122E-D0F7-4CB3-9A7C-6A82E58092E1Q51206705-2B91971A-6B4E-48F6-B123-C708B4BF59EE
P2860
Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Salirasib sensitizes hepatocar ...... survivin-dependent mechanisms
@en
Salirasib sensitizes hepatocar ...... survivin-dependent mechanisms.
@nl
type
label
Salirasib sensitizes hepatocar ...... survivin-dependent mechanisms
@en
Salirasib sensitizes hepatocar ...... survivin-dependent mechanisms.
@nl
prefLabel
Salirasib sensitizes hepatocar ...... survivin-dependent mechanisms
@en
Salirasib sensitizes hepatocar ...... survivin-dependent mechanisms.
@nl
P2093
P2860
P356
P1476
Salirasib sensitizes hepatocar ...... survivin-dependent mechanisms
@en
P2093
C De Saeger
I Leclercq
N Charette
Y Horsmans
P2860
P2888
P356
10.1038/CDDIS.2012.200
P577
2013-01-24T00:00:00Z
P5875
P6179
1036527251